Eli Lilly and Company Aktie News

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply chains.

Eli Lilly said it will spend $6 billion to build a manufacturing plant in Huntsville, Alabama, to help boost production of its closely watched experimental obesity pill, orforglipron, and other drugs.  It is the third facility in a string of new planned U.S. investments by the drugmaker.

Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 bi...

This company is a leader in a market that may approach $100 billion in a few years. This player's key products are delivering billion-dollar revenue.

Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.

INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)  and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 pe...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition, and were featured as part of the meeting's press...